Literature DB >> 22525521

Examination of the carboxylesterase phenotype in human liver.

Matthew K Ross1, Abdolsamad Borazjani, Ran Wang, J Allen Crow, Shuqi Xie.   

Abstract

Carboxylesterases (CES) metabolize esters. Two CES isoforms are expressed in human liver (CES1 and CES2) and liver extracts are used in reaction phenotyping studies to discern interindividual metabolic variation. We tested the hypothesis that an individual's CES phenotype can be characterized by reporter substrates/probes that interrogate native CES1 and CES2 activities in liver and immunoblotting methods. We obtained 25 livers and found that CES1 is the main hydrolytic enzyme. Moreover, although CES1 protein levels were similar, we observed large interindividual variation in bioresmethrin hydrolysis rates (17-fold), a pyrethroid metabolized by CES1 but not CES2. Bioresmethrin hydrolysis rates did not correlate with CES1 protein levels. In contrast, procaine hydrolysis rates, a drug metabolized by CES2 but not CES1, were much less variant (3-fold). Using activity-based fluorophosphonate probes (FP-biotin), which covalently reacts with active serine hydrolases, CES1 protein was the most active enzyme in the livers. Finally, using bioorthogonal probes and click chemistry methodology, the half-life of CES 1 and 2 in cultured HepG2 cells was estimated at 96 h. The cause of the differential CES1 activities is unknown, but the underlying factors will be important to understand because several carboxylic acid ester drugs and environmental toxicants are metabolized by this enzyme.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525521      PMCID: PMC3569858          DOI: 10.1016/j.abb.2012.04.010

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  54 in total

Review 1.  Decoding protein modifications using top-down mass spectrometry.

Authors:  Nertila Siuti; Neil L Kelleher
Journal:  Nat Methods       Date:  2007-10       Impact factor: 28.547

Review 2.  Activity-based protein profiling: from enzyme chemistry to proteomic chemistry.

Authors:  Benjamin F Cravatt; Aaron T Wright; John W Kozarich
Journal:  Annu Rev Biochem       Date:  2008       Impact factor: 23.643

3.  Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil.

Authors:  Christopher D Fleming; Sompop Bencharit; Carol C Edwards; Janice L Hyatt; Lyudmila Tsurkan; Feng Bai; Charles Fraga; Christopher L Morton; Escher L Howard-Williams; Philip M Potter; Matthew R Redinbo
Journal:  J Mol Biol       Date:  2005-09-09       Impact factor: 5.469

4.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

Authors:  Bin Li; Meghan Sedlacek; Indumathi Manoharan; Rathnam Boopathy; Ellen G Duysen; Patrick Masson; Oksana Lockridge
Journal:  Biochem Pharmacol       Date:  2005-10-06       Impact factor: 5.858

5.  Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon.

Authors:  J Allen Crow; Victoria Bittles; Katye L Herring; Abdolsamad Borazjani; Philip M Potter; Matthew K Ross
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-04       Impact factor: 4.219

6.  Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.

Authors:  Fabrizio d'Esposito; Noelia Nebot; Robert J Edwards; Michael Murray
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

7.  Identification of rat and human cytochrome p450 isoforms and a rat serum esterase that metabolize the pyrethroid insecticides deltamethrin and esfenvalerate.

Authors:  Stephen J Godin; J Allen Crow; Edward J Scollon; Michael F Hughes; Michael J DeVito; Matthew K Ross
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

8.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; Hong-Jie Yuan; Jun-Sheng Wang; Jennifer L Donovan; C Lindsay DeVane; Robert Malcolm; Julie A Johnson; Geri L Youngblood; Douglas H Sweet; Taimour Y Langaee; John S Markowitz
Journal:  Am J Hum Genet       Date:  2008-05-15       Impact factor: 11.025

9.  Carboxylesterases: Dual roles in lipid and pesticide metabolism.

Authors:  Matthew K Ross; Timothy M Streit; Katye L Herring
Journal:  J Pestic Sci       Date:  2010       Impact factor: 1.519

10.  Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases.

Authors:  J Allen Crow; Abdolsamad Borazjani; Philip M Potter; Matthew K Ross
Journal:  Toxicol Appl Pharmacol       Date:  2007-03-12       Impact factor: 4.219

View more
  23 in total

1.  The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.

Authors:  Claus Stage; Gesche Jürgens; Louise Schow Guski; Ragnar Thomsen; Ditte Bjerre; Laura Ferrero-Miliani; Yassine Kamal Lyauk; Henrik Berg Rasmussen; Kim Dalhoff
Journal:  Br J Clin Pharmacol       Date:  2017-02-24       Impact factor: 4.335

2.  Catalytic Reaction Mechanism for Drug Metabolism in Human Carboxylesterase-1: Cocaine Hydrolysis Pathway.

Authors:  Jianzhuang Yao; Xiabin Chen; Fang Zheng; Chang-Guo Zhan
Journal:  Mol Pharm       Date:  2018-08-10       Impact factor: 4.939

3.  Silencing carboxylesterase 1 in human THP-1 macrophages perturbs genes regulated by PPARγ/RXR and RAR/RXR: down-regulation of CYP27A1-LXRα signaling.

Authors:  Lee C Mangum; Xiang Hou; Abdolsamad Borazjani; Jung Hwa Lee; Matthew K Ross; J Allen Crow
Journal:  Biochem J       Date:  2018-02-09       Impact factor: 3.857

4.  A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.

Authors:  Xinwen Wang; Nada Rida; Jian Shi; Audrey H Wu; Barry E Bleske; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2017-08-24       Impact factor: 3.922

Review 5.  Enzyme-Instructed Self-Assembly for Cancer Therapy and Imaging.

Authors:  Beom Jin Kim; Bing Xu
Journal:  Bioconjug Chem       Date:  2020-02-07       Impact factor: 4.774

6.  Lipopolysaccharide suppresses carboxylesterase 2g activity and 2-arachidonoylglycerol hydrolysis: A possible mechanism to regulate inflammation.

Authors:  Brittany Szafran; Abdolsamad Borazjani; Jung Hwa Lee; Matthew K Ross; Barbara L F Kaplan
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-09-25       Impact factor: 3.072

7.  Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.

Authors:  Hao Xu; Jaimeen D Majmudar; Dahvid Davda; Phani Ghanakota; Ki H Kim; Heather A Carlson; Hollis D Showalter; Brent R Martin; Gordon L Amidon
Journal:  Mol Pharm       Date:  2015-08-17       Impact factor: 4.939

8.  Development of amide-based fluorescent probes for selective measurement of carboxylesterase 1 activity in tissue extracts.

Authors:  Sean D Kodani; Morgane Barthélemy; Shizuo G Kamita; Bruce Hammock; Christophe Morisseau
Journal:  Anal Biochem       Date:  2017-10-18       Impact factor: 3.365

9.  Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.

Authors:  Jian Shi; Xinwen Wang; Jenny Nguyen; Audrey H Wu; Barry E Bleske; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2016-01-27       Impact factor: 3.922

10.  Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.

Authors:  Jian Shi; Xinwen Wang; Rachel F Eyler; Yan Liang; Li Liu; Bruce A Mueller; Hao-Jie Zhu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2016-07-21       Impact factor: 4.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.